156 related articles for article (PubMed ID: 31418397)
21. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH
Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137
[TBL] [Abstract][Full Text] [Related]
22. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.
González García A; Fernández-Martín J; Robles Marhuenda Á
Rheumatology (Oxford); 2023 Apr; 62(4):1426-1435. PubMed ID: 35997567
[TBL] [Abstract][Full Text] [Related]
23. The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
Horna P; King RL; Jevremovic D; Fajgenbaum DC; Dispenzieri A
Haematologica; 2023 Jan; 108(1):207-218. PubMed ID: 35484648
[TBL] [Abstract][Full Text] [Related]
24. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
25. Lung transplantation for idiopathic multicentric Castleman disease: potential efficacy and tolerability of a humanized anti-interleukin-6 receptor monoclonal antibody.
Tomioka Y; Otani S; Tanaka S; Shien K; Suzawa K; Miyoshi K; Yamamoto H; Okazaki M; Sugimoto S; Yamane M; Toyooka S
Surg Case Rep; 2021 Sep; 7(1):209. PubMed ID: 34533616
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
[TBL] [Abstract][Full Text] [Related]
27. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Fajgenbaum DC; van Rhee F; Nabel CS
Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
[TBL] [Abstract][Full Text] [Related]
28. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
[TBL] [Abstract][Full Text] [Related]
29. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.
Srkalovic G; Nijim S; Srkalovic MB; Fajgenbaum D
Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927535
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy.
Mukherjee S; Martin R; Sande B; Paige JS; Fajgenbaum DC
Blood Adv; 2022 Jan; 6(2):359-367. PubMed ID: 34535010
[TBL] [Abstract][Full Text] [Related]
31. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
32. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
[TBL] [Abstract][Full Text] [Related]
33. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
Zhang L; Zhao AL; Duan MH; Li ZY; Cao XX; Feng J; Zhou DB; Zhong DR; Fajgenbaum DC; Li J
Blood; 2019 Apr; 133(16):1720-1728. PubMed ID: 30760451
[TBL] [Abstract][Full Text] [Related]
35. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
36. CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
Pierson SK; Katz L; Williams R; Mumau M; Gonzalez M; Guzman S; Rubenstein A; Oromendia AB; Beineke P; Fosså A; van Rhee F; Fajgenbaum DC
Nat Commun; 2022 Nov; 13(1):7236. PubMed ID: 36433996
[TBL] [Abstract][Full Text] [Related]
37. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
[TBL] [Abstract][Full Text] [Related]
38. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
Lang E; van Rhee F
Blood Rev; 2024 Mar; 64():101161. PubMed ID: 38087716
[TBL] [Abstract][Full Text] [Related]
39. Targeting the mTOR pathway in idiopathic multicentric Castleman disease.
Stern RM; Berliner N
J Clin Invest; 2019 Oct; 129(10):4086-4088. PubMed ID: 31524635
[TBL] [Abstract][Full Text] [Related]
40. Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease.
Harada T; Kikushige Y; Miyamoto T; Uno K; Niiro H; Kawakami A; Koga T; Akashi K; Yoshizaki K
Nat Commun; 2023 Oct; 14(1):6959. PubMed ID: 37907518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]